During the COVID-19 pandemic, on 27 March 2020, the Minister of Health commissioned the Agency to develop, in collaboration with the Expert Panel, the first version of the Recommendations in COVID-19. In view of the dynamically changing pandemic situation and the continuous influx of new scientific evidence for the clinical efficacy and safety of medical technologies used in COVID-19, the is engaged in a process of continuously updating the Recommendations.
Reviews of scientific reports for individual drug technologies in COVID-19 (systemic glucocorticoids, lopinavir + ritonavir, remdesivir, tocilizumab, favipiravir and convalescent plasma, anakinra, interferon beta, amantadine, hydroxychloroquine and chloroquine, anticoagulants, clopidogrel / acetylsalicyclic acid , bamlanivimab ± etesevimab, ivermectin, regdanvimab, REGN-COV2, sotrovimab, lenzilumab, baricitinib, inhaled glucocorticoids, human immunoglobulins, mesenchymal stem cells, antibiotics, sarilumab, tofacitinib, sulodexide, fluvoxamine, or molnupiravir, nirmatrelvir+ritonavir). Analytical studies form the basis of the discussion in the Clinical Expert Panel.
Collection of updated COVID-19 pharmacotherapy recommendations:
*Ladies and Gentlemen
We inform you that the materials and results of the discussions posted on the Agency’s website are the result of the conceptual work and analytical process carried out by the team of the Agency for Health Technology Assessment and Tariff System based on the EBM paradigm, including: search, selection, synthesis and interpretation of scientific evidence, or the data analysis carried out .
In connection with the above, we would like to inform you that the use of analytical material or the results of the discussion, in accordance with good practice, should be accompanied by information on the source in the form: [title of presentation / report], AOTMiT, Warsaw, June 2021]